Cargando…

Functionalized TiO(2) nanoparticles labelled with (225)Ac for targeted alpha radionuclide therapy

The (225)Ac radioisotope exhibits very attractive nuclear properties for application in radionuclide therapy. Unfortunately, the major challenge for radioconjugates labelled with (225)Ac is that traditional chelating moieties are unable to sequester the radioactive daughters in the bioconjugate whic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cędrowska, Edyta, Pruszynski, Marek, Majkowska-Pilip, Agnieszka, Męczyńska-Wielgosz, Sylwia, Bruchertseifer, Frank, Morgenstern, Alfred, Bilewicz, Aleksander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Netherlands 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861168/ https://www.ncbi.nlm.nih.gov/pubmed/29576738 http://dx.doi.org/10.1007/s11051-018-4181-y

Ejemplares similares

Trastuzumab Modified Barium Ferrite Magnetic Nanoparticles Labeled with Radium-223: A New Potential Radiobioconjugate for Alpha Radioimmunotherapy
por: Gawęda, Weronika, et al.
Publicado: (2020)

Trastuzumab Conjugated Superparamagnetic Iron Oxide Nanoparticles Labeled with (225)Ac as a Perspective Tool for Combined α-Radioimmunotherapy and Magnetic Hyperthermia of HER2-Positive Breast Cancer
por: Cędrowska, Edyta, et al.
Publicado: (2020)

Effect of Surface Functionalization on the Cellular Uptake and Toxicity of Nanozeolite A
por: Męczyńska-Wielgosz, Sylwia, et al.
Publicado: (2016)

Functionalized NaA nanozeolites labeled with (224,225)Ra for targeted alpha therapy
por: Piotrowska, Agata, et al.
Publicado: (2013)

First preclinical evaluation of [(225)Ac]Ac-DOTA-JR11 and comparison with [(177)Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs
por: Handula, Maryana, et al.
Publicado: (2023)

Dose escalation study of targeted alpha therapy with [(225)Ac]Ac-DOTA-substance P in recurrence glioblastoma – safety and efficacy
por: Królicki, Leszek, et al.
Publicado: (2021)

Nanoparticles in Targeted Alpha Therapy
por: Majkowska-Pilip, Agnieszka, et al.
Publicado: (2020)

Cubosomal Lipid Formulation for Combination Cancer Treatment: Delivery of a Chemotherapeutic Agent and Complexed α-Particle Emitter (213)Bi
por: Cytryniak, Adrianna, et al.
Publicado: (2022)

Development of [(225)Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC
por: Hooijman, Eline L., et al.
Publicado: (2021)

Radium and Francium beam tests to produce 225Ac/ 213Bi generators at CERN-MEDICIS
por: Bruchertseifer, Frank, et al.
Publicado: (2015)

α-Zirconium(IV) Phosphate: Static Study of (225)Ac Sorption in an Acidic Environment and Its Kinetic Sorption Study Using (nat)Eu as a Model System for (225)Ac
por: Ondrák, Lukáš, et al.
Publicado: (2023)

Preclinical Evaluation of (225)Ac-Labeled Single-Domain Antibody for the Treatment of HER2(pos) Cancer
por: Rodak, Magdalena, et al.
Publicado: (2022)

Carbonic Anhydrase IX-Targeted α-Radionuclide Therapy with 225Ac Inhibits Tumor Growth in a Renal Cell Carcinoma Model
por: Merkx, Robin I. J., et al.
Publicado: (2022)

An Overview of Targeted Alpha Therapy with (225)Actinium and (213)Bismuth
por: Morgenstern, Alfred, et al.
Publicado: (2018)

Au@Pt Core-Shell Nanoparticle Bioconjugates for the Therapy of HER2+ Breast Cancer and Hepatocellular Carcinoma. Model Studies on the Applicability of (193m)Pt and (195m)Pt Radionuclides in Auger Electron Therapy
por: Wawrowicz, Kamil, et al.
Publicado: (2021)

Design and Evaluation of (223)Ra-Labeled and Anti-PSMA Targeted NaA Nanozeolites for Prostate Cancer Therapy–Part I
por: Czerwińska, Malwina, et al.
Publicado: (2020)

Multifunctional Nanoparticles Based on Iron Oxide and Gold-198 Designed for Magnetic Hyperthermia and Radionuclide Therapy as a Potential Tool for Combined HER2-Positive Cancer Treatment
por: Żuk, Michał, et al.
Publicado: (2022)

Trastuzumab-Modified Gold Nanoparticles Labeled with (211)At as a Prospective Tool for Local Treatment of HER2-Positive Breast Cancer
por: Dziawer, Łucja, et al.
Publicado: (2019)

Supply and Clinical Application of Actinium-225 and Bismuth-213
por: Morgenstern, Alfred, et al.
Publicado: (2020)

1,2-Benzenedithiol and Toluene-3,4-dithiol Arsenic(III) Complexes—Synthesis, Structure, Spectroscopic Characterization and Toxicological Studies
por: Lyczko, Monika, et al.
Publicado: (2019)

DNA Double Strand Breaks as Predictor of Efficacy of the Alpha-Particle Emitter Ac-225 and the Electron Emitter Lu-177 for Somatostatin Receptor Targeted Radiotherapy
por: Graf, Franziska, et al.
Publicado: (2014)

(225)Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study
por: Sathekge, Mike, et al.
Publicado: (2018)

[(225)Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer: Preclinical Evaluation and Comparison with [(225)Ac]Ac-PSMA-617
por: Busslinger, Sarah D., et al.
Publicado: (2022)

The in vivo fate of (225)Ac daughter nuclides using polymersomes as a model carrier
por: Kruijff, R. M. de, et al.
Publicado: (2019)

Towards reliable production of 225Ac for medical applications: Systematic analysis of the production of Fr, Ra and Ac beams.
por: Dockx, Kristof, et al.
Publicado: (2017)

The Significance of NK1 Receptor Ligands and Their Application in Targeted Radionuclide Tumour Therapy
por: Majkowska-Pilip, Agnieszka, et al.
Publicado: (2019)

Platinum nanoparticles labelled with iodine-125 for combined “chemo-Auger electron” therapy of hepatocellular carcinoma
por: Wawrowicz, Kamil, et al.
Publicado: (2023)

Resonant laser ionization and mass separation of $^{225}$Ac
por: Johnson, Jake D, et al.
Publicado: (2023)

Resonant laser ionization and mass separation of (225)Ac
por: Johnson, Jake D., et al.
Publicado: (2023)

Dosing (225)Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity
por: Kratochwil, Clemens, et al.
Publicado: (2021)

(225)Ac-MACROPATATE: A Novel α-Particle Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors
por: King, A. Paden, et al.
Publicado: (2023)

Evaluation of Actinium-225 Labeled Minigastrin Analogue [(225)Ac]Ac-DOTA-PP-F11N for Targeted Alpha Particle Therapy
por: Qin, Yun, et al.
Publicado: (2020)

Oxidative Status as an Attribute for Selective Antitumor Activity of Platinum-Containing Nanoparticles against Hepatocellular Carcinoma
por: Wawrowicz, Kamil, et al.
Publicado: (2022)

Doxorubicin- and Trastuzumab-Modified Gold Nanoparticles as Potential Multimodal Agents for Targeted Therapy of HER2+ Cancers
por: Żelechowska-Matysiak, Kinga, et al.
Publicado: (2023)

Advances in (177)Lu-PSMA and (225)Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
por: Ling, Sui Wai, et al.
Publicado: (2022)

Hybrid Radiobioconjugated Superparamagnetic Iron Oxide-Based Nanoparticles for Multimodal Cancer Therapy
por: Żuk, Michał, et al.
Publicado: (2021)

Au@(109)Pd core–shell nanoparticle conjugated to trastuzumab for the therapy of HER2+ cancers: studies on the applicability of (109)Pd/(109m)Ag in vivo generator in combined β(−) auger electron therapy
por: Gharibkandi, Nasrin Abbasi, et al.
Publicado: (2023)

Improvement of the Effectiveness of HER2+ Cancer Therapy by Use of Doxorubicin and Trastuzumab Modified Radioactive Gold Nanoparticles
por: Żelechowska-Matysiak, Kinga, et al.
Publicado: (2023)

(225)Ac-PSMA-617 radioligand therapy of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC): preliminary clinical findings
por: Sathekge, Mike, et al.
Publicado: (2023)

Lipidic Cubic-Phase Nanoparticles (Cubosomes) Loaded with Doxorubicin and Labeled with (177)Lu as a Potential Tool for Combined Chemo and Internal Radiotherapy for Cancers
por: Cytryniak, Adrianna, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9fclghupadc0vrs2rpg2ugprg1